arrow
A

Alice Di Rocco

sapienza university rome
H指数:27
被引数:3,404

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE study

Polatuzumab vedotin-含方案作为桥接CART:CART-SIE研究分析

2026-05-070
OA
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial

通过分析微小残留病动态改善套细胞淋巴瘤的预后预测:意大利淋巴瘤基金会(FIL)MCL0208临床试验数据

2026-04-300
OAAI
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial

基因突变与拷贝数变异的整合优化了套细胞淋巴瘤的预后:意大利淋巴瘤基金会MCL0208临床试验的长期结果

Leukemia
IF13.4
2025-11-070
OAAI
Sustained Remission in Relapsed/Refractory Diffuse Large B Cell Lymphoma Following Glofitamab Discontinuation Due to JC Virus Reactivation: Balancing Efficacy and Infectious Risk

由于JCV病毒再激活停用Glofitamab后,复发/难治性弥漫大B细胞淋巴瘤的持续缓解:平衡疗效与感染风险

2025-11-060
PRE
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study

利妥昔单抗、 bendamustine 和 cytarabine,随后使用 venetoclax 治疗高风险套细胞淋巴瘤老年患者(FIL_V-RBAC):一项多中心、单臂、Ⅱ期研究

2025-09-170
PRE
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

IELSG37试验中免疫化疗方案对原发性纵隔B细胞淋巴瘤患者预后的影响

Blood
IF23.1
2025-09-150
PRE
Routine Prophylaxis with Levetiracetam offers no benefit in CD19 CAR-T for LBCL: a Multicenter Propensity-matched Study

常规使用左乙拉西坦进行预防对LBCL的CD19 CAR-T治疗无益:一项多中心倾向性匹配研究

2025-08-110
OAAI
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

CAR T细胞疗法在高等级B细胞淋巴瘤中的疗效与弥漫大B细胞淋巴瘤的比较:一项加权比较分析

2025-08-070
OAAI
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

FIL MCL0208试验中,来那度胺维持治疗与观察在MCL患者自体干细胞移植(ASCT)后的长期结果

2025-03-220
OAAI
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study

CAR-hematox的前瞻性验证和简化版本预测Anti-CD19 CAR T细胞治疗的大b细胞淋巴瘤患者的生存: 来自cart-sie研究的数据

2025-01-010
OAAI
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024-07-020
OAAI
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
LEUKEMIA
IF13.4
2024-03-084
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI